Everest Medicines Limited (1952.HK)

HKD 50.8

(3.15%)

Net Income Summary of Everest Medicines Limited

Everest Medicines Limited's latest annual net income in 2023 was -844.46 Million CNY , down -241.5% from previous year.
Everest Medicines Limited's latest quarterly net income in 2024 Q2 was -316.2 Million CNY , down 0.0% from previous quarter.
Everest Medicines Limited reported an annual net income of -247.28 Million CNY in 2022, up 75.6% from previous year.
Everest Medicines Limited reported an annual net income of -1.01 Billion CNY in 2021, up 82.16% from previous year.
Everest Medicines Limited reported a quarterly net income of -316.2 Million CNY for 2024 Q1, down -50.27% from previous quarter.
Everest Medicines Limited reported a quarterly net income of -210.42 Million CNY for 2023 Q4, down 0.0% from previous quarter.

Annual Net Income Chart of Everest Medicines Limited (2023 - 2018)

Historical Annual Net Income of Everest Medicines Limited (2023 - 2018)

Year	Net Income	Net Income Growth
2023	-844.46 Million CNY	-241.5%
2022	-247.28 Million CNY	75.6%
2021	-1.01 Billion CNY	82.16%
2020	-5.68 Billion CNY	-2836.85%
2019	-193.47 Million CNY	80.49%
2018	-991.67 Million CNY	0.0%

Year	Net Income	Net Income Growth
2024 Q2	-316.2 Million CNY	0.0%
2024 Q1	-316.2 Million CNY	-50.27%
2023 Q4	-210.42 Million CNY	0.0%
2023 Q2	-211.8 Million CNY	0.0%
2023 FY	-844.46 Million CNY	-241.5%
2023 Q1	-211.8 Million CNY	-200.68%
2023 Q3	-210.42 Million CNY	0.65%
2022 Q3	210.37 Million CNY	162.98%
2022 Q4	210.37 Million CNY	0.0%
2022 Q2	-334.02 Million CNY	0.0%
2022 FY	-247.28 Million CNY	75.6%
2022 Q1	-334.02 Million CNY	-6.78%
2021 Q3	-312.8 Million CNY	-63.3%
2021 Q2	-191.55 Million CNY	0.0%
2021 FY	-1.01 Billion CNY	82.16%
2021 Q1	-191.55 Million CNY	92.39%
2021 Q4	-312.8 Million CNY	0.0%
2020 FY	-5.68 Billion CNY	-2836.85%
2020 Q3	-2.51 Billion CNY	-169.36%
2020 Q2	-934.56 Million CNY	-407.46%
2020 Q4	-2.51 Billion CNY	0.0%
2020 Q1	303.95 Million CNY	0.0%
2019 FY	-193.47 Million CNY	80.49%
2019 Q1	99.12 Million CNY	0.0%
2018 FY	-991.67 Million CNY	0.0%

Peer Net Income Comparison of Everest Medicines Limited

Name	Net Income	Net Income Difference
Uni-Bio Science Group Limited	70.87 Million HKD	1291.465%
CK Life Sciences Int'l., (Holdings) Inc.	17.25 Million HKD	4995.438%